semaglutide fda approved approves higher dose of Wegovy to increase patient weight loss Ozempic is first GLP-1 drug

Mounjaro (GLP-1 and GIP receptor agonist) is FDA-approved for the treatment of type 2 diabetes mellitus

Take progress photos to track changes, as gradual improvements can be hard to notice day-to-day

Body composition and dietary intake As expected, given the short duration of the study, there were no significant changes in subjects BMI, iliac waist circumference, or percent body fat as measured by DEXA during the study (data not shown)

Control Release 211 , 144162 (2015)

GLP-1 receptor agonist use and weight change in patients with breast cancer

Long-term safety considerations Clinical trials have demonstrated the promise of tirzepatide as a new medication for chronic weight management and T2DM